Anchor Therapeutics Raises $10 Million
Anchor Therapeutics, a Cambridge, Mass.-based developer of pepducin drug candidates, has raised $10 million in Series B funding. Return backers include TVM Capital, HealthCare Ventures and the Novartis Option Fund. The company also said it is in talks with other investors for additional Series B financing.
20 August 2010•2 mins read
